BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chronic Hepatitis B readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Chronic Hepatitis B\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05453435-5880@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Entecavir (Baraclude): Phase 2 readout est. (NCT05453435)
DESCRIPTION:Entecavir (Baraclude)\, phase 2\, Chronic Hepatitis B.\nStudy: 
 Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cel
 l Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surfac
 e Antigen\, Positive Hepatitis B Core Antibody)\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 ntecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05453435
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07852091-994@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07852091)
DESCRIPTION:Envafolimab\, phase 2\, Chronic Hepatitis B.\nStudy: A Novel Co
 mbination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepat
 itis B Virus Infection (A)\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07852091
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179575-10218@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:LW231: Phase 1/2 readout est. (NCT07179575)
DESCRIPTION:LW231\, phase 1/2\, Chronic Hepatitis B.\nStudy: Study of LW231
  in Participants With Chronic Hepatitis B\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lw231#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07179575
URL:https://assetmemo.bio/drug/lw231#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03038802-10011@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Hepadvax: Phase 1/2 readout est. (NCT03038802)
DESCRIPTION:Hepadvax\, phase 1/2\, Chronic Hepatitis B.\nStudy: A Randomise
 d Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chron
 ic Hepatitis B Virus Infection\nEstimated primary completion: 1 March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hepadvax#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03038802
URL:https://assetmemo.bio/drug/hepadvax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282249-9842@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:TVAX-008: Phase 3 readout est. (NCT07282249)
DESCRIPTION:TVAX-008\, phase 3\, Chronic Hepatitis B.\nStudy: Clinical Tria
 l to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatme
 nt of Chronic Hepatitis B\nEstimated primary completion: 30 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tvax-008#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07282249
URL:https://assetmemo.bio/drug/tvax-008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06966232-5880@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Entecavir (Baraclude): Phase 3 readout est. (NCT06966232)
DESCRIPTION:Entecavir (Baraclude)\, phase 3\, Chronic Hepatitis B.\nStudy: 
 Prophylactic or Preemptive Entecavir in Patients With Gastrointestinal Can
 cer Who Are Inactive Hepatitis B Carriers\nEstimated primary completion: 1
 5 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/entecavir
 -baraclude#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06966232
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06537414-10996@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Daplusiran/Tomligisiran: Phase 2 readout est. (NCT06537414)
DESCRIPTION:Daplusiran/Tomligisiran\, phase 2\, Chronic Hepatitis B.\nStudy
 : A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Fol
 lowed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB
 )\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06537414
URL:https://assetmemo.bio/drug/daplusiran-tomligisiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07203118-9804@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 2/3 readout est. (NCT0720311
 8)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 2/3\, Chronic Hepatitis
  B.\nStudy: A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chron
 ic Hepatitis B\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07203118
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07267208-5880@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entecavir (Baraclude): Phase 2 readout est. (NCT07267208)
DESCRIPTION:Entecavir (Baraclude)\, phase 2\, Chronic Hepatitis B.\nStudy: 
 A Prospective Study to Evaluate the Efficacy and Safety of Entecavir ODT C
 onversion in Stable Liver Transplant Patients\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 entecavir-baraclude#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07267208
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06092333-9776@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:peginterferon alfa-2a (Pegasys): Phase 2 readout est. (NCT06092333)
DESCRIPTION:peginterferon alfa-2a (Pegasys)\, phase 2\, Chronic Hepatitis B
 .\nStudy: VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B\nEsti
 mated primary completion: 29 February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/peginterferon-alfa-2a-pegasys#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06092333
URL:https://assetmemo.bio/drug/peginterferon-alfa-2a-pegasys#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-5880@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Entecavir (Baraclude): Phase 3 readout est. (NCT07797231)
DESCRIPTION:Entecavir (Baraclude)\, phase 3\, Chronic Hepatitis B.\nStudy: 
 Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogu
 es(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepati
 tis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral L
 oad or Poor Response\nEstimated primary completion: September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/entecavir-baraclude#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07797231
URL:https://assetmemo.bio/drug/entecavir-baraclude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-8395@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT07
 797231)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, Chronic Hepa
 titis B.\nStudy: Clinical Trial of TQA3605 Tablet in Combination With Nucl
 eos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients Wi
 th Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Ex
 hibit Low Viral Load or Poor Response\nEstimated primary completion: Septe
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-
 disoproxil-fumarate-viread#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07797231
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-9804@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:tenofovir alafenamide (Vemlidy): Phase 3 readout est. (NCT07797231)
DESCRIPTION:tenofovir alafenamide (Vemlidy)\, phase 3\, Chronic Hepatitis B
 .\nStudy: Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)I
 de Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chro
 nic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit L
 ow Viral Load or Poor Response\nEstimated primary completion: September 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-alafena
 mide-vemlidy#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07797231
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-vemlidy#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797231-9845@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:TQA3605: Phase 3 readout est. (NCT07797231)
DESCRIPTION:TQA3605\, phase 3\, Chronic Hepatitis B.\nStudy: Clinical Trial
  of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus
  NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus In
 fection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Re
 sponse\nEstimated primary completion: September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tqa3605#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07797231
URL:https://assetmemo.bio/drug/tqa3605#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876856-9842@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280922
DTEND;VALUE=DATE:20280923
SUMMARY:TVAX-008: Phase 1/2 readout est. (NCT07876856)
DESCRIPTION:TVAX-008\, phase 1/2\, Chronic Hepatitis B.\nStudy: A Study of 
 Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection i
 n Participants Living With Chronic Hepatitis B (CHB)\nEstimated primary co
 mpletion: 22 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tvax-008#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07876856
URL:https://assetmemo.bio/drug/tvax-008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897448-9842@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20280922
DTEND;VALUE=DATE:20280923
SUMMARY:TVAX-008: Phase 1/2 readout est. (NCT07897448)
DESCRIPTION:TVAX-008\, phase 1/2\, Chronic Hepatitis B.\nStudy: A Study of 
 Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection i
 n Participants Living With Chronic Hepatitis B (CHB)\nEstimated primary co
 mpletion: 22 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tvax-008#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07897448
URL:https://assetmemo.bio/drug/tvax-008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630727-9884@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:AHB-171: Phase 2 readout est. (NCT07630727)
DESCRIPTION:AHB-171\, phase 2\, Chronic Hepatitis B.\nStudy: Study of AHB-1
 71 in Chronic Hepatitis B Participants\nEstimated primary completion: 31 M
 arch 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ahb-171#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076307
 27
URL:https://assetmemo.bio/drug/ahb-171#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200193-10234@assetmemo.bio
DTSTAMP:20261121T005355Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:CRMA-1001: Phase 1/2 readout est. (NCT07200193)
DESCRIPTION:CRMA-1001\, phase 1/2\, Chronic Hepatitis B.\nStudy: A Phase 1/
 2\, Open-Label\, Single and Multiple Ascending Dose Study of CRMA-1001 in 
 Adults With Chronic Hepatitis B\nEstimated primary completion: February 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/crma-1001#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07200193
URL:https://assetmemo.bio/drug/crma-1001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
